Company Description
Metsera is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions.
We use our proprietary MINT peptide library of NuSH analog peptides alongside our Half-life Augmentation by Lipid Optimization, or HALO, half-life extending platform and our MOMENTUM oral NuSH analog peptide delivery platform to deliver highly differentiated product candidates that we are advancing into clinical trials for obesity or overweight.
MET-097i, our most advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA that we are developing for the treatment of obesity and overweight.
We have an ongoing Phase 1/2 clinical trial of MET-097i in the United States in participants who are obese or overweight but otherwise healthy.
| Country | United States |
| Founded | 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 74 |
| CEO | Christopher Whitten Bernard |
Contact Details
Address: 3 World Trade Center, 175 Greenwich Street New York, NY 10007 United States | |
| Phone | (212) 784-6595 |
| Website | metsera.com |
Stock Details
| Ticker Symbol | MTSR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002040807 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Clive A. Meanwell, M.B., Ch.B., M.D. | Executive Chairman of the Board of Directors |
| Christopher Whitten Bernard | President, Chief Executive Officer and Director |
| Christopher J. Visioli | Chief Financial Officer and Chief Business Officer |
| Steven Marso, M.D. | Chief Medical Officer |
| Brian Hubbard, Ph.D. | Chief Scientific Officer |
| Paul L. Berns | Director |
| Kristina M. Burow | Director |
| Joshua Pinto, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 12, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Nov 20, 2024 | D | Notice of Exempt Offering of Securities |
| Nov 4, 2024 | DRS | [Cover] Draft Registration Statement |